Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Fallopian Tube Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Neoplasms 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Vaccinia 1Uterine Cervical Neoplasms 1Solid Tumors 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1HER2-negative Breast Cancer 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Small Cell 1Breast Diseases 1Brain Neoplasms 1Biliary Tract Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

pembrolizumab 2Docetaxel 2Cisplatin 2Bevacizumab 2130-nm albumin-bound paclitaxel 2taxane 1liposomal doxorubicin 1durvalumab 1cemiplimab 1atezolizumab 1Sorafenib 1Pemetrexed 1Paclitaxel 1Nivolumab 1Irinotecan 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Granulocyte-Macrophage Colony-Stimulating Factor 1Drug Therapy 1Biosimilar Pharmaceuticals 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaccinia × taxane × Clear all
NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡